CCRP practice question 23 of 25
In an IND study, the specified dosage of an investigational product is 2 mg twice a day for 10 days. The product is available in 1 mg tablets. The subject was given 45 tablets and was instructed to take 2 mg of the product twice a day for 10 days. How many tablets should the subject have after the 10 days?
Full set: 130 questionsDomain Investigational Product/Device
The subject is instructed to take 2 mg twice a day. Since the tablets are 1 mg each, the subject must take 2 tablets per dose. With two doses per day, the total daily consumption is 4 tablets (2 tablets/dose x 2 doses/day). Over the 10-day treatment period, the total number of tablets to be consumed is 40 (4 tablets/day x 10 days). The subject was dispensed 45 tablets. Therefore, the number of tablets remaining after 10 days should be 5 (45 dispensed - 40 consumed). This calculation is a fundamental component of investigational product accountability required in clinical trials.
A. 0: This is incorrect as the subject was dispensed 45 tablets but was only instructed to take 40 over the specified period.
B. 1: This represents an incorrect calculation of the remaining tablets based on the prescribed dosage and duration.
D. 20: This represents the total number of 2 mg doses (2 doses/day 10 days), not the number of remaining 1 mg tablets.
1. U.S. Food and Drug Administration (FDA). Code of Federal Regulations Title 21, Part 312.62(a). This regulation mandates that an investigator maintain "adequate records of the disposition of the drug, including dates, quantity, and use by subjects." This directly implies the need for precise accounting of dispensed, used, and returned investigational products.
2. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2016). Guideline for Good Clinical Practice E6(R2), Section 4.6.3. This section states, "The investigator/institution should maintain records of the product's delivery to the trial site, the inventory at the site, the use by each subject, and the return to the sponsor or alternative disposition of unused product(s)." This principle underpins the calculation in the question.
3. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2016). Guideline for Good Clinical Practice E6(R2), Section 5.14.3. This section outlines the sponsor's responsibility for implementing a system for retrieving investigational products and documenting this retrieval (e.g., for reconciliation). This reconciliation process requires accurate counts of returned medication.
Keep practicing
Take the free CCRP practice test
Ten exam-style questions with answers and explanations, plus the exam facts and study guides.
More questions
Other CCRP practice questions
- Question 1The study coordinator for a new Phase III vaccine study is preparing documents for IRB/IE…
- Question 2In a completed multi-site Phase I drug study using remote EDC, who ensures the system com…
- Question 3Which of the following is an example of an additional protection required when conducting…
- Question 4A clinical investigator is planning to conduct a quality of life medical device study in …
- Question 5In accordance with the ICH GCP Guideline, prior to initiating a trial, which of the follo…
- Question 6According to the CFR and the ICH GCP Guideline, which of the following must be submitted …
